Document Detail

Phase I clinical study of quelamycin.
MedLine Citation:
PMID:  361226     Owner:  NLM     Status:  MEDLINE    
A phase I clinical study was done with quelamycin, a recently synthesized triferric derivative of adriamycin. Twenty-one good-risk patients were studied: 19 patients with non-small cell carcinoma of the lung and two patients with metastatic sarcoma. Acute toxicity occurred in all patients and consisted of high fever, flushing, hypertension, generalized body aches, tremors, and confusion, which lasted 3-6 hours. Potentially dangerous cardiotoxicity occurred in eight patients who had previous minor rhythm disturbances, and was characterized by tachycardia, atrial extrasystoles, atrial fibrillation, and branch block which lasted 6-14 hours. The dose-limiting hematologic toxicity was found to occur at 125 mg/m2 iv single-dose. Objective responses were observed in three of 19 patients with lung cancer and in one patient with metastatic osteogenic sarcoma resistant to adriamycin therapy. In conclusion, quelamycin is a new derivative of adriamycin with potential interest. However, the acute generalized toxicity and the immediate cardiotoxicity found in the presently used schedule are excessive. Further studies directed to suppress these side effects are in progress.
A Brugarolas; N Pachon; M Gosalvez; A P Llanderal; A J Lacave; J M Buesa; M G Marco
Related Documents :
20876046 - Dronedarone: an alternative to amiodarone?
6188126 - The induction of atrial flutter and fibrillation and the termination of atrial flutter ...
19165566 - Right atrial spontaneous echo contrast indicates a high incidence of perfusion defects ...
15699536 - Management of oral anticoagulant in clinical practice: a retrospective study of 187 pat...
21884016 - Evaluation of the effects of urotensin ii and soluble epoxide hydrolase inhibitor on sk...
21450986 - Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measur...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Cancer treatment reports     Volume:  62     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1978 Oct 
Date Detail:
Created Date:  1979-01-26     Completed Date:  1979-01-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1527-34     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arrhythmias, Cardiac / chemically induced
Carcinoma / drug therapy*
Clinical Trials as Topic
Doxorubicin / adverse effects,  analogs & derivatives*,  therapeutic use
Drug Evaluation
Ferric Compounds / adverse effects,  therapeutic use
Hematologic Diseases / chemically induced
Lung Neoplasms / drug therapy*
Middle Aged
Neoplasm Metastasis
Sarcoma / drug therapy*
Reg. No./Substance:
0/Ferric Compounds; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
Next Document:  Clinical phase I-II study of cis-dichloro-diammineplatinum(II) given by continuous lv infusion.